Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

PMID:
29203590
2.

Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.

Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA.

Nature. 2017 Mar 30;543(7647):723-727. doi: 10.1038/nature21433. Epub 2017 Mar 22.

3.

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R.

Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23.

4.

Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.

Makkouk A, Sundaram V, Chester C, Chang S, Colevas AD, Sunwoo JB, Maecker H, Desai M, Kohrt HE.

Ann Oncol. 2017 Feb 1;28(2):415-420. doi: 10.1093/annonc/mdw570.

PMID:
27831501
5.

Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning.

Müller AM, Florek M, Kohrt HE, Küpper NJ, Filatenkov A, Linderman JA, Hadeiba H, Negrin RS, Shizuru JA.

J Immunol. 2016 Nov 15;197(10):4151-4162. Epub 2016 Oct 10.

6.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt H, Sznol M, Levy R.

Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. doi: 10.1158/1078-0432.CCR-16-1272. Epub 2016 Oct 18.

7.

Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.

Souza-Fonseca-Guimaraes F, Blake SJ, Makkouk A, Chester C, Kohrt HE, Smyth MJ.

Oncoimmunology. 2016 Jun 30;5(7):e1192740. doi: 10.1080/2162402X.2016.1192740. eCollection 2016 Jul.

8.

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.

Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D.

Oncoimmunology. 2016 May 19;5(7):e1186323. doi: 10.1080/2162402X.2016.1186323. eCollection 2016 Jul.

9.

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.

Liu J, Blake SJ, Harjunpää H, Fairfax KA, Yong MC, Allen S, Kohrt HE, Takeda K, Smyth MJ, Teng MW.

Cancer Res. 2016 Sep 15;76(18):5288-301. doi: 10.1158/0008-5472.CAN-16-0194. Epub 2016 Aug 8.

10.

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.

Gray HJ, Benigno B, Berek J, Chang J, Mason J, Mileshkin L, Mitchell P, Moradi M, Recio FO, Michener CM, Secord AA, Tchabo NE, Chan JK, Young J, Kohrt H, Gargosky SE, Goh JC.

J Immunother Cancer. 2016 Jun 21;4:34. doi: 10.1186/s40425-016-0137-x. eCollection 2016.

11.

Holbrook Edwin Kohrt-In memoriam.

Kohrt H.

Hum Vaccin Immunother. 2016 Oct 2;12(10):2486-2487. doi: 10.1080/21645515.2016.1155937. Epub 2016 May 25. No abstract available.

12.

Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus.

Zhao X, Chester C, Rajasekaran N, He Z, Kohrt HE.

Mol Cancer Ther. 2016 May;15(5):767-73. doi: 10.1158/1535-7163.MCT-15-0695. Epub 2016 Apr 14. Review.

13.

Biomarkers associated with checkpoint inhibitors.

Manson G, Norwood J, Marabelle A, Kohrt H, Houot R.

Ann Oncol. 2016 Jul;27(7):1199-206. doi: 10.1093/annonc/mdw181. Epub 2016 Apr 27. Review.

14.

Leukocyte trafficking: Can we bring the fight to the tumor?

Pachynski R, Nazha J, Kohrt H.

Discov Med. 2016 Mar;21(115):205-12. Review.

15.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA.

N Engl J Med. 2016 Jun 30;374(26):2542-52. doi: 10.1056/NEJMoa1603702. Epub 2016 Apr 19.

16.

4-1BB agonism: adding the accelerator to cancer immunotherapy.

Chester C, Ambulkar S, Kohrt HE.

Cancer Immunol Immunother. 2016 Oct;65(10):1243-8. doi: 10.1007/s00262-016-1829-2. Epub 2016 Mar 31. Review.

17.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

18.

Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.

Yonezawa A, Chester C, Rajasekaran N, Kohrt HE.

Chin Clin Oncol. 2016 Feb;5(1):5. doi: 10.3978/j.issn.2304-3865.2016.02.05. Review. No abstract available.

19.

Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.

Sanmamed MF, Chester C, Melero I, Kohrt H.

Ann Oncol. 2016 Jul;27(7):1190-8. doi: 10.1093/annonc/mdw041. Epub 2016 Feb 23. Review.

PMID:
26912558
20.

CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.

Lee Y, Shin JH, Longmire M, Wang H, Kohrt HE, Chang HY, Sunwoo JB.

Clin Cancer Res. 2016 Jul 15;22(14):3571-81. doi: 10.1158/1078-0432.CCR-15-2665. Epub 2016 Feb 10.

21.

In situ vaccination for the treatment of cancer.

Hammerich L, Bhardwaj N, Kohrt HE, Brody JD.

Immunotherapy. 2016;8(3):315-30. doi: 10.2217/imt.15.120. Epub 2016 Feb 9. Review.

PMID:
26860335
22.

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL Jr, Sallusto F, Rusakiewicz S, Weide B, Marabelle A, Kohrt H, Dalle S, Cavalcanti A, Kroemer G, Di Giacomo AM, Maio M, Wong P, Yuan J, Wolchok J, Umansky V, Eggermont A, Zitvogel L.

J Clin Invest. 2016 Mar 1;126(3):921-37. doi: 10.1172/JCI80071. Epub 2016 Feb 8.

23.

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Semeraro M, Jégou S, Flores C, Chen L, Kwon BS, Borg C, Weide B, Aubin F, Dalle S, Kohrt H, Ayyoub M, Kroemer G, Marabelle A, Cavalcanti A, Eggermont A, Zitvogel L.

J Invest Dermatol. 2016 May;136(5):994-1001. doi: 10.1016/j.jid.2015.12.042. Epub 2016 Jan 29.

24.

Rationale for anti-CD137 cancer immunotherapy.

Makkouk A, Chester C, Kohrt HE.

Eur J Cancer. 2016 Feb;54:112-119. doi: 10.1016/j.ejca.2015.09.026. Epub 2016 Jan 2. Review.

PMID:
26751393
25.

Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy.

Chester C, Fritsch K, Kohrt HE.

Front Immunol. 2015 Dec 2;6:601. doi: 10.3389/fimmu.2015.00601. eCollection 2015. Review.

26.

Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism.

Cartron G, Houot R, Kohrt HE.

Clin Cancer Res. 2016 Feb 15;22(4):787-9. doi: 10.1158/1078-0432.CCR-15-2777. Epub 2015 Dec 18.

27.

A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial.

Tan AC, Goubier A, Kohrt HE.

J Immunother Cancer. 2015 Nov 17;3:48. doi: 10.1186/s40425-015-0093-x. eCollection 2015. Review.

28.

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.

Houot R, Schultz LM, Marabelle A, Kohrt H.

Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190. Review.

29.

Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas.

Hebb J, Kohrt H.

Curr Hematol Malig Rep. 2015 Dec;10(4):438-47. doi: 10.1007/s11899-015-0290-1. Review.

PMID:
26433890
30.

Critical issues in cancer vaccine trial design.

Clifton GT, Kohrt HE, Peoples GE.

Vaccine. 2015 Dec 16;33(51):7386-7392. doi: 10.1016/j.vaccine.2015.09.019. Epub 2015 Sep 19. Review.

PMID:
26392010
31.

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.

Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R.

Bone Marrow Transplant. 2015 Oct;50(10):1286-92. doi: 10.1038/bmt.2015.149. Epub 2015 Jul 6.

32.

In-situ tumor vaccination: Bringing the fight to the tumor.

Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE.

Hum Vaccin Immunother. 2015;11(8):1901-9. doi: 10.1080/21645515.2015.1049779. Review.

33.

Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, Waldmann TA, Garcia KC, Leonard WJ.

Immunity. 2015 May 19;42(5):826-38. doi: 10.1016/j.immuni.2015.04.018.

34.

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Feb 3;4(1):e985940. eCollection 2015 Jan. Review.

35.

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.

Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE.

Clin Cancer Res. 2015 Jul 15;21(14):3113-20. doi: 10.1158/1078-0432.CCR-15-0263. Epub 2015 Apr 23. Review.

36.

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.

Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S.

Clin Cancer Res. 2015 Aug 15;21(16):3727-39. doi: 10.1158/1078-0432.CCR-14-2824. Epub 2015 Apr 13.

37.

Immunotherapeutic approaches to ovarian cancer treatment.

Chester C, Dorigo O, Berek JS, Kohrt H.

J Immunother Cancer. 2015 Mar 24;3:7. doi: 10.1186/s40425-015-0051-7. eCollection 2015. Review.

38.

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.

Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72. doi: 10.1073/pnas.1500712112. Epub 2015 Feb 17.

39.

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R.

Blood. 2015 Mar 26;125(13):2079-86. doi: 10.1182/blood-2014-08-593137. Epub 2015 Feb 6.

40.

New insights into the mechanism of action of immune checkpoint antibodies.

Marabelle A, Kohrt H, Levy R.

Oncoimmunology. 2014 Aug 3;3(8):e954869. eCollection 2014.

41.

CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies.

Houot R, Kohrt H.

Oncoimmunology. 2014 Jul 3;3(7):e941740. eCollection 2014.

42.

Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.

Chester C, Marabelle A, Houot R, Kohrt HE.

Curr Opin Immunol. 2015 Apr;33:1-8. doi: 10.1016/j.coi.2014.12.010. Epub 2015 Jan 7. Review.

PMID:
25576932
43.

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.

Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt HE.

Immunotargets Ther. 2015 May 15;4:91-100. doi: 10.2147/ITT.S61292. eCollection 2015. Review.

44.

Current clinical trials testing combinations of immunotherapy and radiation.

Crittenden M, Kohrt H, Levy R, Jones J, Camphausen K, Dicker A, Demaria S, Formenti S.

Semin Radiat Oncol. 2015 Jan;25(1):54-64. doi: 10.1016/j.semradonc.2014.07.003. Review.

45.

Radiotherapy and toll-like receptor agonists.

Marabelle A, Filatenkov A, Sagiv-Barfi I, Kohrt H.

Semin Radiat Oncol. 2015 Jan;25(1):34-9. doi: 10.1016/j.semradonc.2014.07.006. Review.

PMID:
25481264
46.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS.

Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.

47.

Diffuse high intensity PD-L1 staining in thymic epithelial tumors.

Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA.

J Thorac Oncol. 2015 Mar;10(3):500-8. doi: 10.1097/JTO.0000000000000429.

48.

Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion.

Filatenkov A, Baker J, Müller AM, Ahn GO, Kohrt H, Dutt S, Jensen K, Dejbakhsh-Jones S, Negrin RS, Shizuru JA, Engleman EG, Strober S.

Radiat Res. 2014 Aug;182(2):163-9. doi: 10.1667/RR13471.1. Epub 2014 Jul 3.

49.

Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations.

Madondo MT, Tuyaerts S, Turnbull BB, Vanderstraeten A, Kohrt H, Narasimhan B, Amant F, Quinn M, Plebanski M.

J Transl Med. 2014 Jun 23;12:179. doi: 10.1186/1479-5876-12-179.

50.

Child abuse, disruptive behavior disorders, depression, and salivary cortisol levels among institutionalized and community-residing boys in Mongolia.

Kohrt BA, Hruschka DJ, Kohrt HE, Carrion VG, Waldman ID, Worthman CM.

Asia Pac Psychiatry. 2015 Mar;7(1):7-19. doi: 10.1111/appy.12141. Epub 2014 Jun 3.

PMID:
24890783

Supplemental Content

Support Center